Nexus Energy Services Inc (IBGR)

[TheFinalCD]

This could be INCREDIBLE for PHAR investors


http://s103.photobucket.com/albums/m151/SJJNAMARTIN/UFC%20Ben%20Henderson%20with%20PHAR/?albumview=slideshow








UFC's Fight Fans **MUST SEE** NOW!!!

Ben Henderson and PHAR(.01)

I have info that I believe should change the course of "Aquaprin"
Pharmstar Pharmecueticals FDA "Approved" product, and of course the PPS on PHAR

If you dont know who Ben Henderson let me start by adding he is one of this biggest sport figures in the WORLD right now, because he is in one of biggest sports in the World


The World of mixed Martial Arts and the UFC

I know Ben from being The WEC Champion, because I gave been a advid MMA fan since the late 80's, and know just about everything there is about the sport, and have watched practically all the big fights!



ben was the WEC ( World Extreme Cage Fighting Champion )
and aafter Ben just defeated UFC's Jim Miller Sun Aug 14th in absolutely dominating and amazing fashion Ben Henderson...is NOW in contention for the UFC 155 Pound Title Fight



This has absolutely insane potential for advertising, endorsing contratcts, and over consumer awareness for PHAR

I will have more info coming, But I am so stoked about a stock that I am invloved with, and the #1 sport that I love coming together for unlimited mutual benefits!




NEW! "Aquaprin" Manufacturing Facility NEW! address...WOW!!


***IMAGINE US BEING PART OF A REVOLUTIONARY ASPIRIN THAT SHOULD TAKE THE WORLD BY STORM***

We could be telling our Grandchildren about our involvement!!


http://www.otcmarkets.com/stock/PHAR/company-info

Contact Info
3914 Airport Drive
Wilson, NC, 27896

Here are jusr a few more photos of the NEW! Facility

























PharmStar Pharmaceuticals(PHAR) Marketwire - 05/18/11

Press Release Source: PharmStar Pharmaceuticals, Inc. On Wednesday May 18, 2011, 9:08 am

PharmStar Pharmaceuticals, Inc. Closes on New Facility

ROCKY MOUNT, NC--( - PharmStar Pharmaceuticals, Inc., (Pinksheets:PHAR - News) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has closed a transaction to acquire a new CGMP facility to produce Aquaprin, the Company's primary product, plus other line extensions.


On April 18, 2011, the Company entered into an agreement to purchase the facility, which is located in Wilson, North Carolina. Wilson is the home to many pharmaceutical companies, and has an excellent support system for the industry. The building is next to Walter Kidde's international headquarters.

The move is expected to expedite the Company's commercialization of Aquaprin and complete a 17-year developmental journey for the patented liquid form of aspirin. While the Company continues to target a 12 to 14 month window to bring the product to market, hopes are high that moving to Wilson may help expedite the timeline.

PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation, developing and marketing the original form of Aquaprin.

Mr. Phykitt stated, "Jennifer Lantz, Director of the Economic Development Council, and the city of Wilson has been wonderful in this process, and I am genuinely excited to be back. They told me they wanted us to be here, and they proved it. I am appreciative of all the work they did to help us make this happen quickly."

Mr. Phykitt continued, "This was a monumental day for me, and for the Company. It is a day that we have worked so hard for and have endured to create. I feel that I now can get on with my work of bringing this new product to life and building a great company."

The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.

About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.


Contact:
Contact:PharmStar, Inc. 919-794-7000Email Contact http://www.pharmstarinc.comInvestor Contact: Email Contact Follow Yahoo! Finance on Twitter; become a fan on Facebook.

92m Float as of May,11,2011 & insiders own all the rest 97% of the O/S
http://www.otcmarkets.com/stock/PHAR/company-info

PHAR(.021) NEWS OUT NOW!!!

PharmStar will begin moving into the new facility immediately, and has been preparing for the move over the last 30 days. PharmStar CEO Howard Phykitt founded Granutec, Inc. in 1985 in Wilson, NC before selling the company in 1989. He remained with the company through 1991. Mr. Phykitt then started Health Corporation , developing and marketing the original form of Aquaprin.

The Company did not issue any type of a new debt instrument, nor did the Company dilute its existing common share capital structure in order to finance the transaction, which is consistent with the company's objective of minimizing future dilution of its shareholder base.


http://finance.yahoo.com/news/PharmStar-Pharmaceuticals-Inc-iw-2427996609.html?x=0






-----------------------------

PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM



http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx

((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn

PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million


Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011

PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."

The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."

On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.

"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.

About PharmStar Pharmaceuticals

PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.












PHAR Financials out before yesterdays close showing

31M assets 50k liabilities
92m float as of 5-11-11
Clean balance sheet
FDA Approved "Aquaprin"

also..

Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)

The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."

http://ih.advfn.com/p.php?pid=nmona&article=47333789

3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709


just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798

Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000

The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.



Why PHAR seen here

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099


http://www.pharmstarinc.com/why_aquaprin.html
















avew mslp pele suff tsan kgri